Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

[EN] This is a meeting report of the 3rd Translational Hepatology Meeting held in Alicante, Spain, in October 2021. The meeting, which was organized by the Spanish Association for the Study of the Liver (AEEH), provided an update on the recent advances in the field of basic and translational hepatol...

Descripción completa

Detalles Bibliográficos
Autores: Gallego-Durán, Rocío, Albillos, Agustín, Ampuero, Javier, Arechederra, María, Bañares, Rafael, Blas-García, Ana, Berná, Genoveva, Caparrós, Esther, Delgado, Teresa C., Falcón-Pérez, Juan M., Francés, Rubén, Fernández-Barrena, Fernández-Barrena, Maite G., Graupera, Isabel, Iruzubieta, Paula, Nevzorova, Yulia A., Nogueiras, Rubén, Macías, Rocío I. R., Martín, Franz, Sabio, Guadalupe, Soriano, Germán, Vaquero, Javier, Cubero, Francisco Javier, Gracia-Sancho, Jordi
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/296292
Acceso en línea:http://hdl.handle.net/10261/296292
Access Level:acceso abierto
Palabra clave:MAFLD
MASH
Steatohepatitis
Fibrosis
Hepatocellular carcinoma
Esteatosis
Esteatohepatitis
Carcinoma hepatocelular
Descripción
Sumario:[EN] This is a meeting report of the 3rd Translational Hepatology Meeting held in Alicante, Spain, in October 2021. The meeting, which was organized by the Spanish Association for the Study of the Liver (AEEH), provided an update on the recent advances in the field of basic and translational hepatology, with a particular focus on the molecular and cellular mechanisms and therapeutic targets involved in metabolic-associated fatty liver disease (MAFLD), metabolic-associated steatohepatitis (MASH), cirrhosis and end-stage hepatocellular carcinoma (HCC).